BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
BioCryst Pharmaceuticals Inc
Interest Income Expense
BioCryst Pharmaceuticals Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
|
Interest Income Expense
-$93.5m
|
CAGR 3-Years
-150%
|
CAGR 5-Years
-68%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-19%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$757m
|
CAGR 3-Years
35%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$563.1m
|
CAGR 3-Years
78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is BioCryst Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
-93.5m
USD
Based on the financial report for Dec 31, 2023, BioCryst Pharmaceuticals Inc's Interest Income Expense amounts to -93.5m USD.
What is BioCryst Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-68%
Over the last year, the Interest Income Expense growth was 3%. The average annual Interest Income Expense growth rates for BioCryst Pharmaceuticals Inc have been -150% over the past three years , -68% over the past five years .